Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2009
05/14/2009US20090124701 Use of alkamides for masking an unpleasant flavor
05/14/2009US20090124700 Administering L-lysine-d-amphetamine or salts
05/14/2009US20090124699 Silicone Material for Releasing an Active Molecule
05/14/2009US20090124698 Selective estrogen receptor modulator compositions and methods for treatment of disease
05/14/2009US20090124697 Inhalation formulations of treprostinil
05/14/2009US20090124696 Abuse-resistant amphetamine prodrugs
05/14/2009US20090124695 Prostaglandin e1 and e2 analogs for the treatment of various medical conditions
05/14/2009US20090124694 Method of producing retinyl esters
05/14/2009US20090124693 Cosmetic Compositions Comprising Hydroxyfatty Acids
05/14/2009US20090124692 Methods and pharmaceutical compositions for decorporation of radioactive compounds
05/14/2009US20090124691 Inhibitor of increase in postprandial blood insulin level
05/14/2009US20090124690 Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins
05/14/2009US20090124689 CETP Inhibitors
05/14/2009US20090124688 Prostaglandin reductase inhibitors
05/14/2009US20090124687 Benzofuran Compound and Pharmaceutical Composition Containing the Same
05/14/2009US20090124686 Gsk-3 inhibitors
05/14/2009US20090124685 Agave syrup extract having anticancer activity
05/14/2009US20090124684 Stimulation Of CPT-1 As A Means To Reduce Weight
05/14/2009US20090124683 Mercaptan and seleno-mercaptan compounds and methods of using them
05/14/2009US20090124682 Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity
05/14/2009US20090124681 Beta-lactone compounds
05/14/2009US20090124680 Use of prodrug composition containing naphthoquinone-based compound for manufacture of medicament for treatment or prevention of diseases involving metabolic syndrome
05/14/2009US20090124677 couplilng reaction of 2-(1H-tetrazol-5-yl)phenylboronic acid with 2-butyl-3-(4'-iodobenzyl)-1,3-diazaspiro[4,4]non-1-en-4-one in a solvent e.g. tetrahydrofuran, in presence of inorganic or organic bases ( triethyamine, potassium carbonate etc) with a palladium catalyst containing phosphine ligand
05/14/2009US20090124676 Substituted cyclopentanes having prostaglandin activity
05/14/2009US20090124675 Inhibitors of anti-apoptotic proteins
05/14/2009US20090124674 Method for treating congestive heart failure
05/14/2009US20090124673 Method for treating diabetic nephropathy
05/14/2009US20090124672 Aldh-2 inhibitors in the treatment of psychiatric disorders
05/14/2009US20090124671 Trpv1 antagonists
05/14/2009US20090124670 Method for designing formulation of self-emulsifying preparation
05/14/2009US20090124669 Structural Analogues of Avenanthramides, Their Use in Compositions Useful in the Treatment of Dermatological Disorders
05/14/2009US20090124668 Cyclic derivatives as modulators of chemokine receptor activity
05/14/2009US20090124667 Novel Dual-Use Peptidase Inhibitors as Prodrugs for a Therapy of Inflammatory and Other Diseases
05/14/2009US20090124666 Trpv1 antagonists
05/14/2009US20090124665 Potassium Channel Inhibitors
05/14/2009US20090124664 (R)-Arylalkylamino Derivatives and Pharmaceutical Compositions Containing Them
05/14/2009US20090124663 Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
05/14/2009US20090124662 Migrastatin analogs in the treatment of cancer
05/14/2009US20090124661 Hcv ns3 protease inhibitors
05/14/2009US20090124660 Piperidine Compounds Useful as Malonyl-CoA Decarboxylase Inhibitors
05/14/2009US20090124659 Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors
05/14/2009US20090124658 Treatments for Viral Infections
05/14/2009US20090124657 Pharmaceutical compositions comprising montelukast
05/14/2009US20090124656 Heterocyclic Oxime Compounds a Process for Their Preparation and Pharmaceutical Compositions Containing Them
05/14/2009US20090124655 Heterocyclic derivatives as modulators of ion channels
05/14/2009US20090124654 Aryl and Heteroaryl Compounds, Compositions, Methods of Use
05/14/2009US20090124653 Muscarinic Acetylcholine Receptor Antagonists
05/14/2009US20090124652 Polymorphs of 1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine Ethane-Sulfonate
05/14/2009US20090124651 Catecholamine derivatives and prodrugs thereof
05/14/2009US20090124650 Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
05/14/2009US20090124649 Aza spiro alkane derivatives as inhibitors of metalloproteases
05/14/2009US20090124648 Such as trans-N-[1-(2-fluorophenyl)-S-pyrazoly]-3-ox-ospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide and novel salts, hydrates and polymorphs thereof; neuropeptide y5 (NPY5)
05/14/2009US20090124647 Indole Derivatives as Antitumoral Compounds
05/14/2009US20090124646 Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
05/14/2009US20090124645 Novel Pyrimidine-2,4-Diamine Derivatives and their Use as Modulators of Small-Conductance Calcium-Activated Potassium Channels
05/14/2009US20090124644 Hiv inhibiting 2-(4-cyanophenylamino) pyrimidine derivatives
05/14/2009US20090124643 Use of a Cannabinoid CB1 Receptor Antagonist for Preparation of Drugs Useful for the Prevention and Treatment of Benign Prostatic Hypertrophy
05/14/2009US20090124642 Crystalline forms of Erlotinib HCI and formulations thereof
05/14/2009US20090124641 Mitotic Kinesin Inhibitors
05/14/2009US20090124640 Pyrrolo[3,2-D]Pyrimidin-4-One Derivative as Myeloperoxidase Inhibitor
05/14/2009US20090124639 valacyclovir formulations
05/14/2009US20090124638 Anti-inflammatory pyrazolopyrimidines
05/14/2009US20090124637 Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794
05/14/2009US20090124636 Chemical compounds
05/14/2009US20090124635 Chemical compounds
05/14/2009US20090124634 Novel dipodazine compounds and applications
05/14/2009US20090124633 N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases
05/14/2009US20090124632 Methods and kits related to the topical administration of quinolone antibiotics°
05/14/2009US20090124631 Combination Therapy
05/14/2009US20090124630 N-[4-(2-methoxyphenyl)piperazin-1-yl)butyl]-3,4-dihydro-6-fluoro-2-naphthamide for treating neuropsychological disorder selected from Parkinson's disease, schizophrenia and depression; partial agonists or antagonists of the dopamine D3 receptor
05/14/2009US20090124629 3-(1,2,4-triazol-3ylalkyl) azabriclo (3.1.0) hexane derivatives as modulators of dopamine d3 receptors
05/14/2009US20090124628 polo-like kinase inhibitors used as antiproliferative and antitumor agents
05/14/2009US20090124627 Compositions for sleeping disorders
05/14/2009US20090124626 Pharmaceutical agent comprising insulin resistance improving agent
05/14/2009US20090124625 Novel alkynyl derivatives as modulators of metatropic glutamate receptors
05/14/2009US20090124624 Substituted 1-aminophthalazine derivatives, preparation thereof and therapeutic application thereof
05/14/2009US20090124623 Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
05/14/2009US20090124622 Medicament Containing a Thiazole Derivative as an Active Ingredient
05/14/2009US20090124621 Pyrazole derivatives as kinase inhibitors
05/14/2009US20090124620 Plasminogen activator inhibitor-1 inhibitor
05/14/2009US20090124619 Novel compounds
05/14/2009US20090124618 2-morpholino-4-pyrimidone compound
05/14/2009US20090124617 Quinolone derivative or salt thereof
05/14/2009US20090124616 7-nonsubstituted indole mcl-1 inhibitors
05/14/2009US20090124615 3-[((1R)-1-{2-Chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl}ethyl)oxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide; polo like kinase enzyme inhibitors; anticarcinogenic agents for treating cancer
05/14/2009US20090124614 Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders
05/14/2009US20090124613 Substituted Heterocyclic Ethers and Their Use in CNS Disorders
05/14/2009US20090124612 Fused heterocyclic derivatives and methods of use
05/14/2009US20090124611 Pyrazolopyridine-1,4-Diamines and Analogs Thereof
05/14/2009US20090124610 Pharmaceutical compounds
05/14/2009US20090124609 Fused heterocyclic derivatives and methods of use
05/14/2009US20090124608 CB2 Receptor Modulators In Neurodegenerative Diseases And Applications Of The Same
05/14/2009US20090124607 Novel Bicyclic Sulfonamides for Use as Glucocorticoid Receptor Modulators in the Treatment of Inflammatory Diseases
05/14/2009US20090124606 Composition for Treatment of Psychosis
05/14/2009US20090124605 Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors
05/14/2009US20090124604 4-oxoquinazolin-3-yl benzamide derivatives for the treatment of cytokine diseases
05/14/2009US20090124603 Diazepan Orexin Receptor Antagonists
05/14/2009US20090124602 Kinase inhibitors
05/14/2009US20090124601 Tartaric Acid Salts of a Dipeptidyl Peptidase-IV Inhibitor
05/14/2009US20090124600 N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists
1 ... 2734 2735 2736 2737 2738 2739 2740 2741 2742 2743 2744 2745 2746 2747 2748 2749 2750 2751 2752 2753 2754 ... 7860